Lu Yang

Lu Yang

Auto-generated profile, based on publicly available information

Lu Yang

Affiliations Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China, Suining Central Hospital, Suining, Sichuan, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LYLu Yang
Lu Yang
LYLei Yu
Lei Yu
XDXue Du
Xue Du
YCYu Cui
Yu Cui
GDGuobo Du
Guobo Du
Background: To study the efficacy and safety of Polyethylene glycolated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the prevention of neutropenia during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC). Methods: This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. Participants were divided into an experimental group and a control group. The experimental group received PEG-rhG-CSF injections post-chemotherapy cycles, whereas the control group received standard care without additional intervention. Outcomes assessed included grade 3/4 neutropenia incidence, blood cell count changes, febrile neutropenia rates, delays or interruptions in chemotherapy/radiotherapy due to hematological toxicity, oral mucositis incidents, and bone pain occurrences, comparing these between both groups. Results: 1. 88 patients with locally advanced NPC were included, the incidence of grade 3 neutropenia in the experimental group was lower than that in the control group (P = 0.026); 2. The white blood cell count and neutrophil count in D7, D10, D14, and D21 in the experimental group were higher than those in the control group (P<0.01); 3. The rate of delayed chemotherapy in the experimental group was lower than that in the control group (2.3% vs. 29.5%), P = 0.001; the rate of interruption of radiotherapy in the experimental group was lower than that in the control group (2.3% vs.27.3%), P = 0.003; 4. The incidence of bone pain in the experimental group was 34.1%, of which most were mild bone pain, and no severe bone pain occurred. The leukocyte and neutrophil counts of the patients in the bone pain group were significantly higher than those of the patients in the no bone pain group, P(WBC) = 0.001, P(ANC) = 0.002. Conclusions: The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.

13 June 2022 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
LYLu Yang
Lu Yang
YCYu Cui
Yu Cui
XDXue Du
Xue Du
BTBangxian Tan
Bangxian Tan
Diffuse large B-cell lymphoma of the frontal sinus is a very rare malignant tumor with atypical clinical manifestations. It usually involves the orbital and ethmoid sinuses and causes vision loss, visual field damage, and nasal obstruction as the first symptoms. Herein, we report the diagnosis and treatment of a patient with diffuse large B-cell lymphoma of the frontal sinus, introduce imaging features of the disease, and discuss the differential diagnosis and treatment of the disease.

3 January 2025 in Cancer Control
Verified
Journal Article
Open access
LYLu Yang
Lu Yang
YGYufeng Gu
Yufeng Gu
LYLei Yu
Lei Yu
QZQiang Zhou
Qiang Zhou
LLLi Liu
Li Liu
NLNa Li
Na Li
Objective: Our study aimed to update demographic profiles of sinonasal adenocarcinoma (SNAC) between 2000 and 2020, identify independent prognostic risk factors, and devise a predictive nomogram for overall survival (OS). Methods: Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, cases of SNAC from 2000 to 2020 were analyzed for incidence trends. Univariate and multivariate Cox regression models helped pinpoint factors impacting patient survival. A prognostic nomogram was then created based on these factors and assessed via concordance index, ROC analysis, and calibration curves. Results: Analysis of 488 SNAC patients indicated a rising incidence, peaking among 60-69-year-olds, with a male predominance and the highest occurrence in White populations. Common sites of occurrence included the nasal cavity, and the maxillary and ethmoid sinuses. The nomogram, developed with 184 patients, highlighted older age (≥70), male sex, advanced T stages (T4b, T4a), distant metastasis, larger tumors (≥5 cm), and lack of surgery as poor prognostic indicators. Nomogram performance demonstrated strong predictive capabilities in both training and validation cohorts. Conclusion: This investigation, leveraging the SEER database, elucidates the epidemiology of SNAC and pinpoints key adverse prognostic determinants: age ≥70, male gender, T stages T4b and T4a, presence of distant metastasis, tumor size exceeding 5 cm, and absence of surgical intervention. Moreover, it introduces a novel nomogram capable of accurately forecasting 1-, 3-, and 5-year OS for SNAC patients, thereby enhancing disease comprehension and facilitating the formulation of tailored therapeutic strategies by clinicians.